Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$113.71

-0.03 (-0.03%)

06:49
08/13/19
08/13
06:49
08/13/19
06:49

Eli Lilly announces Taltz meets primary, secondary endpoints in IXORA-R trial

Eli Lilly announced Taltz met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus Tremfya in people living with moderate to severe plaque psoriasis, or PsO. The IXORA-R trial is the first completed head-to-head, or H2H, trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index, or PASI, 100 score as the primary endpoint. At 12 weeks, Taltz met the primary endpoint by demonstrating superiority in the proportion of patients achieving complete skin clearance compared to Tremfya as measured by PASI 100. In addition, Taltz met all major secondary endpoints up to week 12, which include superiority over Tremfya in the proportion of patients achieving PASI 75 at Week 2, PASI 90 at Weeks 4 and 8, PASI 100 at Weeks 4 and 8, static Physician's Global Assessment, or sPGA, 0 at Week 12 and PASI 50 at Week 1. Lilly plans to share results on the remaining key secondary endpoint of proportion of patients achieving PASI 100 at 24 weeks in 2020. A total of 1,027 patients with moderate to severe plaque psoriasis were enrolled in the study to evaluate the efficacy and safety of Taltz compared to Tremfya. Participants were randomized to receive Taltz or Tremfya for a total of 24 weeks, with the primary analysis conducted at 12 weeks. In IXORA-R, the safety profile of Taltz was consistent with previously reported results. No new safety signals were detected. Lilly plans to submit detailed data from the IXORA-R study for disclosure at scientific meetings and in peer-reviewed journals.

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

  • 23

    Oct

LLY Eli Lilly
$113.71

-0.03 (-0.03%)

06/11/19
JPMS
06/11/19
NO CHANGE
JPMS
Overweight
Eli Lilly Rewind data missed 'fairly high' expectations, says JPMorgan
JPMorgan analyst Chris Schott is not surprised by the weakness yesterday in shares of Eli Lilly as he believes the Rewind data came in below "fairly high" expectations. However, the analyst ultimately sees the data confirming a cardiovascular benefit for Trulicity and supporting "continued strong Trulicity/GLP-1 uptake." Further, Schott sees the tirzepatide data at the American Diabetes Association conference as continuing to highlight a potentially best in class efficacy profile for the product. Lilly remains the analyst's top pick in his pharma coverage.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/17/19
MZHO
07/17/19
NO CHANGE
Target $103
MZHO
Buy
Amgen seen by Mizuho as 'most likely' buyer of Celgene's Otezla
In the wake of the recent announcement that Bristol-Myers (BMY) plans to divest Otezla as part of its deal to acquire Celgene (CELG), Mizuho analyst Salim Syed said he has received questions on who could be a realistic buyer. He believes the "most likely" buyer would be Amgen (AMGN), followed by Johnson & Johnson (JNJ), which he would label as a "likely" buyer. Syed identifies the "less likely, but possible" buyers as Eli Lilly (LLY) and Regeneron (REGN). The analyst, who said Otezla is worth anywhere from $5B-$10B depending on the view of sales and synergy potential, keeps a Buy rating and $103 price target on Celgene shares.
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

09:57
08/21/19
08/21
09:57
08/21/19
09:57
Conference/Events
The Food & Drug Law Institute to hold a webinar »

Anthony Anscombe, Partner…

GLD

SPDR Gold Shares

$141.65

-0.56 (-0.39%)

09:56
08/21/19
08/21
09:56
08/21/19
09:56
Options
Upside call Seller in SPDR Gold Trust »

Upside call Seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$99.51

13.935 (16.28%)

, LOW

Lowe's

$109.03

10.985 (11.20%)

09:55
08/21/19
08/21
09:55
08/21/19
09:55
Options
Early notable gainers among liquid option names on August 21st »

Notable gainers among…

TGT

Target

$99.51

13.935 (16.28%)

LOW

Lowe's

$109.03

10.985 (11.20%)

BBBY

Bed Bath & Beyond

$8.06

0.32 (4.13%)

URBN

Urban Outfitters

$21.97

1.04 (4.97%)

PCG

PG&E

$11.67

0.04 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 11

    Nov

  • 19

    Nov

GNTX

Gentex

$26.73

0.26 (0.98%)

09:55
08/21/19
08/21
09:55
08/21/19
09:55
Conference/Events
Gentex to hold analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

DKS

Dick's Sporting

$32.70

0.35 (1.08%)

, AOBC

American Outdoor Brands

$7.61

(0.00%)

09:54
08/21/19
08/21
09:54
08/21/19
09:54
Periodicals
Dick's Sporting testing if company should stop selling guns, CNN reports »

Dick's Sporting…

DKS

Dick's Sporting

$32.70

0.35 (1.08%)

AOBC

American Outdoor Brands

$7.61

(0.00%)

RGR

Sturm, Ruger

$40.73

(0.00%)

VSTO

Vista Outdoor

$4.90

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 29

    Aug

  • 10

    Sep

  • 19

    Sep

EADSY

Airbus

$0.00

(0.00%)

, GE

General Electric

$8.37

-0.02 (-0.24%)

09:51
08/21/19
08/21
09:51
08/21/19
09:51
Periodicals
Engine Alliance to order checks after 2017 A380 engine explosion, Reuters says »

Investigators examining…

EADSY

Airbus

$0.00

(0.00%)

GE

General Electric

$8.37

-0.02 (-0.24%)

UTX

United Technologies

$127.63

0.96 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 03

    Sep

  • 09

    Sep

  • 30

    Oct

09:50
08/21/19
08/21
09:50
08/21/19
09:50
General news
U.S. existing home sales preview: »

U.S. existing home sales…

09:50
08/21/19
08/21
09:50
08/21/19
09:50
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

MSGN

MSG Networks

$15.67

-1.18 (-7.00%)

09:48
08/21/19
08/21
09:48
08/21/19
09:48
Downgrade
MSG Networks rating change  »

MSG Networks downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

AFL

Aflac

$50.29

-1.57 (-3.03%)

09:48
08/21/19
08/21
09:48
08/21/19
09:48
Periodicals
Aflac cancer insurance policies mis-sold by Japan Post, The Mainichi reports »

Japan Post mis-sold about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$29.42

-2.08 (-6.60%)

09:47
08/21/19
08/21
09:47
08/21/19
09:47
Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF falls -6.7% »

ProShares Trust Ultra VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$15.67

-1.18 (-7.00%)

09:47
08/21/19
08/21
09:47
08/21/19
09:47
Hot Stocks
MSG Networks falls -6.8% »

MSG Networks is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

JMIA

Jumia Technologies

$12.03

-2.66 (-18.11%)

09:47
08/21/19
08/21
09:47
08/21/19
09:47
Hot Stocks
Jumia Technologies falls -17.8% »

Jumia Technologies is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

GSX

GSX Techedu

$15.66

1.01 (6.89%)

09:47
08/21/19
08/21
09:47
08/21/19
09:47
Hot Stocks
GSX Techedu rises 6.9% »

GSX Techedu is up 6.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

LOW

Lowe's

$109.52

11.48 (11.71%)

09:47
08/21/19
08/21
09:47
08/21/19
09:47
Hot Stocks
Lowe's rises 12.0% »

Lowe's is up 12.0%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 25

    Sep

TGT

Target

$98.54

12.965 (15.15%)

09:47
08/21/19
08/21
09:47
08/21/19
09:47
Hot Stocks
Target rises 15.2% »

Target is up 15.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

WKHS

Workhorse Group

$3.80

0.165 (4.54%)

, GM

General Motors

$37.28

0.32 (0.87%)

09:46
08/21/19
08/21
09:46
08/21/19
09:46
Hot Stocks
Workhorse Group up 9% in early trading »

Shares of Workhorse Group…

WKHS

Workhorse Group

$3.80

0.165 (4.54%)

GM

General Motors

$37.28

0.32 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

09:45
08/21/19
08/21
09:45
08/21/19
09:45
General news
Existing Home Sales to be reported at 10:00 »

July Existing Home Sales…

KSS

Kohl's

$44.87

(0.00%)

09:42
08/21/19
08/21
09:42
08/21/19
09:42
Recommendations
Kohl's analyst commentary at Guggenheim »

Kohl's [price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$210.35

(0.00%)

, AMGN

Amgen

$203.15

(0.00%)

09:41
08/21/19
08/21
09:41
08/21/19
09:41
Periodicals
Apple, Amgen, Cisco all slowed buyback spending in Q2, WSJ says »

S&P Dow Jones Indices…

AAPL

Apple

$210.35

(0.00%)

AMGN

Amgen

$203.15

(0.00%)

CSCO

Cisco

$47.94

(0.00%)

BAC

Bank of America

$26.72

(0.00%)

ORCL

Oracle

$53.00

(0.00%)

JPM

JPMorgan

$107.33

(0.00%)

WFC

Wells Fargo

$44.70

(0.00%)

MSFT

Microsoft

$137.25

(0.00%)

JCI

Johnson Controls

$42.34

(0.00%)

GOOGL

Alphabet Class A

$1,184.26

(0.00%)

GOOG

Alphabet

$1,183.43

(0.00%)

C

Citi

$63.44

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 04

    Sep

  • 06

    Sep

  • 09

    Sep

  • 09

    Sep

  • 10

    Sep

  • 16

    Sep

  • 19

    Sep

  • 24

    Sep

  • 10

    Oct

  • 12

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

  • 13

    Nov

URBN

Urban Outfitters

$20.93

(0.00%)

, LOW

Lowe's

$98.04

(0.00%)

09:40
08/21/19
08/21
09:40
08/21/19
09:40
Options
Unusually active option classes on open August 21st »

Unusual total active…

URBN

Urban Outfitters

$20.93

(0.00%)

LOW

Lowe's

$98.04

(0.00%)

PDD

Pinduoduo

$25.97

(0.00%)

FIT

Fitbit

$2.94

(0.00%)

FCX

Freeport McMoRan

$9.19

(0.00%)

HD

Home Depot

$217.14

(0.00%)

TLRY

Tilray

$29.30

(0.00%)

RIG

Transocean

$4.58

(0.00%)

XBI

SPDR S&P BIOTECH

$82.47

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 10

    Sep

  • 23

    Sep

  • 25

    Sep

  • 19

    Nov

  • 19

    Nov

CLR

Continental Resources

$30.57

-0.65 (-2.08%)

09:39
08/21/19
08/21
09:39
08/21/19
09:39
Recommendations
Continental Resources analyst commentary  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$82.98

2.13 (2.63%)

09:37
08/21/19
08/21
09:37
08/21/19
09:37
Conference/Events
Nevro participates in a conference call with SVB Leerink »

SVB Leerink holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 09

    Sep

TGT

Target

$85.57

-0.34 (-0.40%)

09:36
08/21/19
08/21
09:36
08/21/19
09:36
Options
Pre-earnings call sale in Target turns ugly as shares jump »

Pre-earnings call sale in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

PAVM

PAVmed

$1.00

(0.00%)

09:33
08/21/19
08/21
09:33
08/21/19
09:33
Hot Stocks
PAVmed announces issuance of U.S. patent »

PAVmed announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.